About Envol Biomedical
Envol Biomedical, established in 2019, is a growing preclinical contract research organization with a mission to be the leading nonhuman primate research facility in the country for the pharmaceutical industry.
The company has access to the largest population of NHP in the US, with lead times for new studies of 4-6 weeks. The laboratory has capabilities in multiple dose routes (including CNS, ophthalmic), specialized disease models and surgical collections. We have access to NHP resources that include cynomolgus macaque of numerous origins, marmosets, squirrel monkeys and African Green. The laboratory is supported by a clinical pathology and immunology core laboratory. Envol is AAALAC accredited, USDA and OLAW compliant.
Our business model is to provide our clients a high value research partner through speed, customer service and quality. We have a strong workforce that is managed by a leadership team with significant CRO and pharmaceutical industry experience. Envol aims to be GLP compliant in 2025.
Non-human primate preclinical research
Largest population available in the continental U.S.
On time delivery of study samples and study reports
AAALAC accredited, USDA and OLAW compliant
Pharmacology and Toxicology Research Facilities
Leadership
Jake McDonald, PhD, ATS
Chief Executive Officer
Oscar Sanchez
Vice President of Quality Assurance and Regulatory Affairs
Dr. Alain Stricker-Krongrad, Ph.D., M.Sc.
Technical Advisor and Co-Founder
Bruce Bernacky, DVM
Attending Veterinarian
Technical Area Leads
Miao Zhong, Ph.D
Pharmacology and Immunology/Bioanalytical
David S. Moddrelle
Director of Surgical Research Services